Portal de Periódicos da CAPES

mRNA-based dendritic cell vaccines

2014; Informa; Volume: 14; Issue: 2 Linguagem: Inglês

10.1586/14760584.2014.957684

1744-8395

Daphné Benteyn, Carlo Heirman, Aude Bonehill, Kris Thielemans, Karine Breckpot,

CAR-T cell therapy research

Cancer immunotherapy has been proposed as a powerful treatment modality. Active immunotherapy aspires to stimulate the patient’s immune system, particularly T cells. These cells can recognize and kill cancer cells and can form an immunological memory. Dendritic cells (DCs) are the professional antigen-presenting cells of our immune system. They take up and process antigens to present them to T cells. Consequently, DCs have been investigated as a means to stimulate cancer-specific T-cell responses. An efficient strategy to program DCs is the use of mRNA, a well-defined and safe molecule that can be easily generated at high purity. Importantly, vaccines consisting of mRNA-modified DCs showed promising results in clinical trials. Therefore, we will introduce cancer immunotherapy and DCs and give a detailed overview on the application of mRNA to generate cancer-fighting DC vaccines.